Related references
Note: Only part of the references are listed.Not Just Genomewide Association Studies Rare Variants in Genes Not Identified Through Genomewide Association Studies Also Contribute to Hypertriglyceridemia
David Evans et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2012)
A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network
Stella Aslibekyan et al.
PHARMACOGENETICS AND GENOMICS (2012)
Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia
Ariel Brautbar et al.
ATHEROSCLEROSIS (2011)
Lipoprotein association studies: taking stock and moving forward
Philippa J. Talmud et al.
CURRENT OPINION IN LIPIDOLOGY (2011)
Genome-Wide Interaction-Based Association Analysis Identified Multiple New Susceptibility Loci for Common Diseases
Yang Liu et al.
PLOS GENETICS (2011)
Investigation of Variants Identified in Caucasian Genome-Wide Association Studies for Plasma High-Density Lipoprotein Cholesterol and Triglycerides Levels in Mexican Dyslipidemic Study Samples
Daphna Weissglas-Volkov et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2010)
Apolipoprotein E Polymorphisms and Postprandial Triglyceridemia Before and After Fenofibrate Treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study
Marguerite R. Irvin et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2010)
Biological, clinical and population relevance of 95 loci for blood lipids
Tanya M. Teslovich et al.
NATURE (2010)
PXR agonism decreases plasma HDL levels in ApoE*3-Leiden.CETP mice
Willeke de Haan et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2009)
Common variants at 30 loci contribute to polygenic dyslipidemia
Sekar Kathiresan et al.
NATURE GENETICS (2009)
Cardiovascular pharmacogenomics and individualized drug therapy
Naveen L. Pereira et al.
NATURE REVIEWS CARDIOLOGY (2009)
Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the Genetics of Lipid-Lowering Drugs and Diet Network study
Yongjun Liu et al.
PHARMACOGENETICS AND GENOMICS (2009)
The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment
Jennifer A. Smith et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2008)
Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression
Caroline C. van der Hoogt et al.
JOURNAL OF LIPID RESEARCH (2007)
The-256T>C polymorphism in the apolipoprotein A-II gene promoter is associated with body mass index and food intake in the genetics of lipid lowering drugs and diet network study
Dolores Corella et al.
CLINICAL CHEMISTRY (2007)
Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy
Gerd Schmitz et al.
CURRENT OPINION IN LIPIDOLOGY (2007)
A promoter polymorphism in cholesterol 7α-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin
K Kajinami et al.
ATHEROSCLEROSIS (2005)
Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes
C Foucher et al.
PHARMACOGENETICS (2004)
Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans
HJ Cordell
HUMAN MOLECULAR GENETICS (2002)
Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients
D Brisson et al.
PHARMACOGENETICS (2002)
Lipids and pulmonary function in the Third National Health and Nutrition Examination Survey
DJ Cirillo et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2002)
Share Paper
